0000899243-19-002654.txt : 20190205
0000899243-19-002654.hdr.sgml : 20190205
20190205172723
ACCESSION NUMBER: 0000899243-19-002654
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190201
FILED AS OF DATE: 20190205
DATE AS OF CHANGE: 20190205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fairey William
CENTRAL INDEX KEY: 0001727275
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37609
FILM NUMBER: 19568999
MAIL ADDRESS:
STREET 1: C/O CHEMOCENTRYX, INC.
STREET 2: 850 MAUDE AVE.
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MyoKardia Inc
CENTRAL INDEX KEY: 0001552451
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 455500552
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 333 ALLERTON AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-741-0900
MAIL ADDRESS:
STREET 1: 333 ALLERTON AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-02-01
0
0001552451
MyoKardia Inc
MYOK
0001727275
Fairey William
C/O MYOKARDIA, INC.
333 ALLERTON AVENUE
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
See Remarks
Stock Option (Right to Buy)
40.99
2019-02-01
4
A
0
69500
0.00
A
2029-01-31
Common Stock
69500
69500
D
Restricted Stock Units
2019-02-01
4
A
0
32500
0.00
A
Common Stock
32500
32500
D
The option shall vest and become exercisable as to 25% of the option on February 1, 2020 and in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The units shall vest in four annual installments after February 1, 2019, subject to the Reporting Person's continuous service to the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer.
Executive Vice President, Chief Commercial Officer
/s/ Cynthia Ladd as Attorney-in-Fact
2019-02-05